Strategic Acquisitions, New Drug Applications, Licensing Agreements, and Financial Results - Research Report on Horizon Pharma, NPS Pharmaceuticals, Spherix, Evoke Pharma, and POZEN Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, November 22, 2013 NEW YORK, November 22, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Horizon Pharma, Inc. (NASDAQ: HZNP), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Spherix Inc. (NASDAQ: SPEX), Evoke Pharma, Inc. (NASDAQ: EVOK), and POZEN Inc. (NASDAQ: POZN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Horizon Pharma, Inc. Research Report On November 19, 2013, Horizon Pharma Inc. (Horizon) announced that it has entered into an agreement to acquire the U.S. rights to VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets from AstraZeneca AB. According to the Company, this agreement further expands Horizon's focus on key primary care physician targets in the U.S. Horizon informed that VIMOVO is approved in the U.S. to relieve the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of stomach ulcers in patients at risk of developing stomach ulcers from treatment with NSAIDs. "The acquisition of VIMOVO is a major step forward in our strategy to leverage our business model and maximize our commercial infrastructure and we expect it to create significant value for our shareholders," stated Timothy P. Walbert, Chairman, President and CEO of Horizon. "We anticipate that this transaction will significantly increase our revenues and accelerate the Company to profitable operations." The Full Research Report on Horizon Pharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s=DDD http://www.analystscorner.com/r/full_research_report/05ea_HZNP -- NPS Pharmaceuticals, Inc. Research Report On November 13, 2013, NPS Pharmaceuticals, Inc. (NPS Pharmaceuticals) announced that its Supplemental New Drug Application for Gattex® (teduglutide [rDNA origin]) for injection has been accepted for review by the Food and Drug Administration. In the US, Gattex is indicated for the treatment of adult patients with Short Bowel Syndrome who are dependent on parenteral support. "We are pleased that the FDA has accepted our sNDA for review," said Roger Garceau, MD, FAAP, Executive Vice President and Chief Medical Officer of NPS Pharmaceuticals. "The data from STEPS 2 we're proposing to include in the label show that patients on Gattex treatment beyond one year continue to achieve clinically meaningful reductions in parenteral support requirements, with some achieving complete independence." The Full Research Report on NPS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s= http://www.analystscorner.com/r/full_research_report/441a_NPSP -- Spherix Inc. Research Report On November 19, 2013, Spherix Inc. (Spherix) announced that its wholly owned subsidiary, CompuFill LLC, has entered into a settlement and license agreement with a leading technology company. This is the first settlement and license agreement for the CompuFill portfolio since Spherix acquired North South Holdings LLC in September 2013. The Company informed that the ongoing infringement enforcement continues as Spherix's model of patent monetization grows in both scope and size. Anthony Hayes, Spherix CEO, stated, "The value of having this suite of patents cannot be emphasized enough. Our team of patent monetization experts brought this opportunity to Spherix only a few short months ago and we have already started generating revenue. This is a great example of how Spherix continues working to drive value for our investors." The Full Research Report on Spherix Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s= http://www.analystscorner.com/r/full_research_report/94a2_SPEX -- Evoke Pharma, Inc. Research Report On November 13, 2013, Evoke Pharma Inc. (Evoke Pharma) reported its Q3 2013 financial results with net loss of $0.5 million, or $0.41 per share, relatively in line with the net loss reported in Q3 2012. R&D expenses totaled $79,000 compared to $337,000 in Q3 2012. According to the Company, the year-over-year decrease was primarily related to the decline in clinical development-related costs as a larger portion of the labor cost was allocated to general and administrative in 2013 as the Company prepared for its initial public offering. On September 24, 2013, Evoke priced its initial public offering of 2.1 million shares of common stock at $12.00 per share. Dave Gonyer, R.Ph., President and CEO, stated, "With the net proceeds of our initial public offering, we are well capitalized to move forward with the planned Phase 3 trial for EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus." The Full Research Report on Evoke Pharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s= http://www.analystscorner.com/r/full_research_report/9af3_EVOK -- POZEN Inc. Research Report On November 6, 2013, POZEN Inc. (POZEN) reported its Q3 2013 financial results with revenue of $2.6 million compared to $0.9 million in Q3 2012. Operating expenses for the quarter totaled $7.4 million, compared to $6.7 million for Q3 2012. POZEN stated that the increase in operating expenses was primarily a result of one-time costs associated with the PA8140/PA32540 agreement with Sanofi US totaling $1.6 million. The Company reported a net loss of $4.8 million or $0.16 loss per share during the quarter, compared to a net loss of $5.7 million or $0.19 per share in Q3 2012. The Full Research Report on POZEN Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: http://analystscorner.com/microwriter/link.php?s= http://www.analystscorner.com/r/full_research_report/f226_POZN ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com SOURCE Analysts' Corner Contact: Joe Thomas, +1-310-496-8071 (North America)
Strategic Acquisitions, New Drug Applications, Licensing Agreements, and Financial Results - Research Report on Horizon Pharma,
Press spacebar to pause and continue. Press esc to stop.